Figure 4.

PFS according to NIK expression. Kaplan‐Meier analysis of PFS with IRd and placebo‐Rd in the RNAseq‐evaluable population based on (A) NIK expression, dichotomized as NIK‐high and NIK‐low based on the global median, and (B) NIK expression by quartile, showing only the lowest (q1) and highest (q4) NIK expression quartiles in each treatment group. CI, confidence interval; HR, hazard ratio; IRd, ixazomib‐lenalidomide‐dexamethasone; NR, not reached; PFS, progression‐free survival; q, quartile; Rd, placebo‐lenalidomide‐dexamethasone; RNAseq, RNA sequencing